Neurocrine Biosciences Inc NBIX
2 targets with a reported result
Releases of the last 3 yearsThe numbers NBIX said it expected, in its earnings releases, next to what it then reported for the same period.
Target by target
Each target, with the sentence it came from · release and 10-Q or 10-K
| Target | What the company said | Reported | Result | |
|---|---|---|---|---|
| Revenue Fiscal 2026 |
Given $2.70B to $2.80B release Feb 11, 2026
Kept $2.70B to $2.80B release May 5, 2026
Raised $2.83B to $2.88B release Jul 30, 2026
Raised $2.90B to $2.92B release Nov 2, 2026
|
– | Not reported yet | |
The company's words® (valbenazine) Full Year 2026 Net Product Sales Guidance of $2.7 - $2.8 Billion release Feb 11, 2026 Reaffirmed 2026 Full-Year INGREZZA ® (valbenazine) Net Sales Guidance of $2.7 - $2.8 Billion release May 5, 2026 ® (valbenazine) 2026 Net Sales Guidance Raised to $2.825 to $2.875 Billion release Jul 30, 2026 ® (valbenazine) 2026 Net Sales Guidance Raised to $2.9 to $2.925 Billion release Nov 2, 2026 | ||||
| Revenue Fiscal 2025 (ended Dec 31, 2025) |
Given $2.50B to $2.60B release Feb 6, 2025
Kept $2.50B to $2.60B release May 5, 2025
Lowered $2.50B to $2.55B release Jul 30, 2025
|
$2.86B 10-K filed 2026-02-11 |
Above the range | |
The company's words(valbenazine) Full Year 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion release Feb 6, 2025 We are reaffirming 2025 INGREZZA net sales guidance of $2.5 to $2.6 billion,” said Kyle W. Gano, Ph.D., Chief Executive Officer of Neurocrine Biosciences. release May 5, 2025 INGREZZA 2025 net product sales guidance narrowed from $2.5 - $2.6 billion to $2.5 - $2.55 billion reflecting double-digit volume growth partially offset by lower net price due to expanded access. release Jul 30, 2025 | ||||
| Revenue Fiscal 2024 (ended Dec 31, 2024) |
Given $2.10B to $2.20B release Feb 7, 2024
Raised $2.25B to $2.30B release Aug 1, 2024
Raised $2.30B to $2.32B release Oct 30, 2024
|
$2.36B 10-K filed 2025-02-10 |
Above the range | |
The company's words(valbenazine) Full Year 2024 Net Product Sales Guidance of $2.1 - $2.2 Billion release Feb 7, 2024 (valbenazine) 2024 Net Product Sales Guidance Raised to $2.25 - $2.3 Billion release Aug 1, 2024 (valbenazine) 2024 Net Product Sales Guidance Raised to $2.30 - $2.32 Billion release Oct 30, 2024 | ||||
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (12 releases since 2024-02-07), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.
Sources
The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.
Also
Earnings releases: each release in full.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/NBIX/export.csv") into a cell.